11400 WEST OLYMPIC BLVD., LOS ANGELES, CA
Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
Immix Biopharma Enters Amendment No. 1 to At The Market Offering Agreement
Underwriting Agreement for 19.1M Shares at $5.10 per Share
Immix Biopharma's Positive Phase 2 NXC-201 Results at ASH 2025
Other Events
News, Securities Holder Rights or Indentures, Material Contracts
Submission of Matters to a Vote of Security Holders
Material Contracts
Amended Annual Report
FY 2025
Q3
Q2
Amended Quarterly Report
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Submission Upload
Correspondence
Free Writing Prospectus